Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | F2R | P25116 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696193 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| SCHEMBL4138087 | 0.97 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| SCHEMBL9830370 | 0.97 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| SCHEMBL9829153 | 0.94 | ITGB3 (0.59) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| Formic Acid SCHEMBL27557118 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| SCHEMBL5424938 | 0.88 | LMNA (0.61) | SMN1; SMN2LMNARECQLCCR5KMT2A | |
| SCHEMBL4130312 | 0.85 | RECQL (0.62) | SMN1; SMN2LMNARECQLCCR5KMT2A | |
| SCHEMBL13326739 | 0.85 | TDP1 (0.65) | SMN1; SMN2LMNARECQLCCR5KCNQ3 | |
| SCHEMBL14218307 | 0.85 | ITGB3 (0.60) | SMN1; SMN2LMNARECQLITGB3ITGA2B | |
| SCHEMBL3882540 | 0.85 | ITGB3 (0.60) | SMN1; SMN2LMNARECQLITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1987036-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093520-A1 | HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191335-A1 | 4-{2-[5-(4,6-Dimethyl-pyrimidine-5-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-ethyl}-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester,chemokine receptor antagonist; human immunodeficiency virus (HIV) infection, AIDS or ARC, antiinflammatory agent, autoimmune diseases, graft v. host disease | CCR5, CXCR1, CXCR3 | SMN1; SMN2 4099/4885LMNA 4654/4885RECQL 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.